Effect of Silymarin Administration on Cisplatin Nephrotoxicity: Report from A Pilot, Randomized, Double‐Blinded, Placebo‐Controlled Clinical Trial
- 7 April 2015
- journal article
- research article
- Published by Wiley in Phytotherapy Research
- Vol. 29 (7) , 1046-1053
Abstract
Despite several introduced preventive modalities, cisplatin nephrotoxicity remains a clinical problem. Some in vitro and in vivo studies have addressed the protective effects of silymarin against cisplatin nephrotoxicity. This study evaluated the effects of silymarin administration on cisplatin nephrotoxicity as the first human study. During this pilot, randomized, double‐blinded, placebo‐controlled clinical trial, the effect of oral silymarin 420 mg daily in three divided doses starting 24–48 h before the initiation of cisplatin infusion and continuing to the end of three 21‐day cisplatin‐containing chemotherapy courses on cisplatin‐induced renal electrolytes wasting and kidney function were assessed. Cisplatin‐associated acute kidney injury (AKI) occurred in 8% of the patients. Urine neutrophil gelatinase‐associated lipocalin to urine creatinine ratio (NGAL/Cr) and urinary magnesium and potassium wasting increased significantly after cisplatin infusion in both groups. Significant positive correlation was found between cumulative dose of cisplatin and urine NGAL/Cr after three courses of cisplatin infusion. Incidence of AKI and the magnitude of urinary magnesium and potassium wasting did not differ between silymarin and placebo groups. No adverse reaction was reported by silymarin administration. Prophylactic administration of conventional form of silymarin tablets could not prevent cisplatin‐induced urine electrolyte wasting or renal function impairment. Copyright © 2015 John Wiley & Sons, Ltd.Keywords
Funding Information
- Tehran University of Medical Sciences (18878)
This publication has 35 references indexed in Scilit:
- Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challengesClinical Kidney Journal, 2012
- Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patientsWorld Journal of Gastroenterology, 2011
- Mechanisms of Cisplatin NephrotoxicityToxins, 2010
- Neutrophil Gelatinase‐Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross‐sectional study and the effects of lisinoprilDiabetic Medicine, 2010
- Predicting Cisplatin-Induced Acute Kidney Injury by Urinary Neutrophil Gelatinase-Associated Lipocalin Excretion: A Pilot Prospective Case-Control StudyNephron Clinical Practice, 2010
- Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis CThe Journal of Clinical Pharmacology, 2010
- Two Flavonolignans from Milk Thistle (Silybum marianum) Inhibit CYP2C9-Mediated Warfarin Metabolism at Clinically Achievable ConcentrationsThe Journal of Pharmacology and Experimental Therapeutics, 2010
- A randomized, controlled, double‐blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL)Cancer, 2009
- Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injuryCritical Care, 2007
- MELD and Other Factors Associated with Survival after Liver TransplantationAmerican Journal of Transplantation, 2004